Evidence map›Paper›PMID 37978159›Full record

Trial reportPaediatric drugs2024

Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach.

Naïm Bouazza, Gilles Cambonie, Cyril Flamant, Aline Rideau, Manon Tauzin, Juliana Patkai, Géraldine Gascoin, Mirka Lumia, Outi Aikio, Gabrielle Lui and 10 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Paediatric drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04459117 (Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04459117 phase2 / phase3completednot on this map

Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen

TypeinterventionalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2020 to 2024Enrolled804ConditionsPatency of the Ductus Arteriosus, Acetaminophen, Extreme PrematurityArmsAcetaminophen, NACL 0.9%
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 2 countries.

Naïm BouazzaEA 7323, Université Paris Cité, Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Paris, France. naim.bouazza@aphp.fr.
Gilles CambonieDepartment of Neonatal Medicine and Pediatric Intensive Care, Arnaud de Villeneuve Hospital, Montpellier University Hospital, 371 Avenue du Doyen Giraud, 34295, Montpellier, France.
Cyril FlamantDepartment of Neonatology, CHU Nantes, Nantes, France.
Aline RideauDepartment of Pediatrics, Robert Debré Hospital, APHP, Paris, France.
Manon TauzinNeonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
Juliana PatkaiNeonatology Department, Port-Royal Hospital, 75014, Paris, France.
Géraldine GascoinDepartment of Neonatology, Angers University Hospital, Angers, France.
Mirka LumiaDepartment of Children and Adolescents, New Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Outi AikioDepartment of Pediatrics and Adolescent Medicine, Oulu University Hospital, and Research Unit of Clinical Medicine and MRC Oulu, University of Oulu, Oulu, Finland.
Gabrielle LuiService de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre, Paris, France.
Léo Froelicher BournaudService de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre, Paris, France.
Aisling Walsh-PapageorgiouEuropean Foundation for the Care of Newborn Infants, Munich, Germany.
Marine TortigueNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
Alban-Elouen BaruteauNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
Jaana KallioDepartment of Children and Adolescents, New Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Mikko HallmanDepartment of Pediatrics and Adolescent Medicine, Oulu University Hospital, and Research Unit of Clinical Medicine and MRC Oulu, University of Oulu, Oulu, Finland.
Alpha DialloClinical Trial Safety and Public Health, ANRS|Emerging Infectious Diseases, Paris, France.
Léa LevoyerClinical Trial Safety and Public Health, ANRS|Emerging Infectious Diseases, Paris, France.
Jean-Marc TreluyerEA 7323, Université Paris Cité, Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Paris, France.
Jean-Christophe RozeNantes Université, CHU Nantes, INSERM, CIC FEA 1413, Nantes, France.
Agence Nationale de Recherches sur le Sida et les Hépatites Virales · FRUniversity of Oulu · FIAssistance Publique – Hôpitaux de Paris · FRGroupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale · FRHelsinki University Hospital · FIHôpital Arnaud de Villeneuve · FRHôpital Cochin · FRHôpital Intercommunal de Créteil · FRHôpital Robert-Debré · FRInserm · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRMaternité Port Royal · FRNantes Université · FRSorbonne Paris Cité · FRUniversité d'Angers · FRUniversity of Helsinki · FI

Funding

Innovative Medicines Initiatives 2 Join Grant Agreement n°777389
6 · The paper itself

Abstract

backgroundPatent ductus arteriosus (PDA) in preterm infants is associated with increased morbidities and mortality. Prophylactic treatment with cyclooxygenase inhibitors, as indomethacin or ibuprofen, failed to demonstrate significant clinical benefits. Acetaminophen may represent an alternative treatment option.

objectiveThis study evaluated the minimum effective dose of prophylactic acetaminophen to close the ductus and assessed the safety and tolerability profile in extremely preterm infants at 23-26 weeks of gestation.

methodsA dose finding trial with Bayesian continual reassessment method was performed in a multicenter study with premature infants hospitalized in neonatal intensive care unit. Infants of 23-26 weeks of gestation and post-natal age ≤ 12 h were enrolled. Four intravenous acetaminophen dose levels were predefined. The primary outcome was the ductus arteriosus closing at two consecutive echocardiographies or at day 7. The main secondary objectives included the safety of acetaminophen on hemodynamics and biological hepatic function.

resultsA total of 29 patients were analyzed sequentially for the primary analysis with 20 infants assigned to the first dose level followed by 9 infants to the second dose level. No further dose level increase was necessary. The posterior probabilities of success, estimated from the Bayesian logistic model, were 46.1% [95% probability interval (PI), 24.9-63.9] and 67.6% (95% PI, 51.5-77.9) for dose level 1 and 2, respectively. A closing or closed pattern was observed among 19 patients at the end of treatment [65.5% (95% confidence interval (CI), 45.7-82.0)]. No change in alanine aminotransferase values was observed during treatment. A significant decrease in aspartate aminotransferase values was observed with postnatal age. No change in systolic and diastolic blood pressures was observed during treatment.

conclusionsMinimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.

trial registrationClinicalTrials.gov Identifier: NCT04459117.

Indexed as

AcetaminophenDuctus Arteriosus, PatentBayes TheoremHumansIbuprofenIndomethacinInfant, Extremely PrematureInfant, NewbornAcetaminophenIbuprofenIndomethacin

Identifiers

PMID37978159
PMCPMC10770203
OpenAlexW4388757148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.